COST-EFFECTIVENESS CONSEQUENCES OF OBESITY IN T2DM BY INSULIN ANALOGUE THERAPY

被引：0
|
作者：
Jozsa, Z. [1 ]
Toth, E. [2 ]
Nagy, B. [2 ]
机构：
[1] Novo Nordisk Hungary Ltd, Budapest, Hungary
[2] Healthware Ltd, Budapest, Hungary
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72090-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF INSULIN DETEMIR IN T2DM PATIENTS POORLY CONTROLLED WITH NPH INSULIN IN POLAND
    Kaczor, M. P.
    Pawlik, D.
    Wojcik, R.
    Jurkiewicz, B.
    VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
  • [2] COST-EFFECTIVENESS ANALYSIS FOR SOLIQUA IN THE TREATMENT OF T2DM IN TURKIYE
    Atikeler, K.
    Kurnaz, M.
    Ileri, S.
    Cansever, M.
    Kahveci, S.
    Kader, B.
    Duran, C.
    Akbay, E. E.
    Karacar, G.
    Ozturk, F.
    Okcun, S.
    Kockaya, G.
    VALUE IN HEALTH, 2023, 26 (12) : S112 - S112
  • [3] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [4] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [5] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [6] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [7] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in the Canadian payer setting
    Kapor, Jovana
    Minshall, Michael E.
    Tunis, Sandra L.
    Conner, Chris
    Mccormick, John
    Seager, Christine
    Groleau, Danielle
    DIABETES, 2008, 57 : A98 - A98
  • [8] Treating T2DM with Early Insulin Therapy
    Agarwal, Amit
    Norton, Pamela
    McNamara, John
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2010, 30 (09): : 49 - +
  • [9] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [10] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFOZIN VERSUS OTHER T2DM TREATMENTS IN THE SPANISH CONTEXT
    Abad Paniagua, E. J.
    Casado Escribano, P.
    Fernandez Rodriguez, J. M.
    Morales Escobar, F. J.
    Canal Fontcuberta, C.
    Betegon Nicolas, L.
    Capel, M.
    Brosa, M.
    VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
12345